Agilent Technologies Inc

Agilent Technologies raised its full-year fiscal 2026 earnings per share guidance to $6.18 to $6.21, excluding the net benefit of tariff refunds, earnings per share of $6.12 to $6.15 are now expected, after reporting third-quarter revenue of $1.88 billion, up 7.3% on a core basis, with China growing 9% despite minimal stimulus benefit. The company now expects full-year revenue of $7.49 billion to $7.51 billion, implying fourth-quarter revenue of $1.98 billion to $2 billion and EPS of $1.71 to $1.74. CEO Padraig McDonnell cited strong pharma growth of 12%, advanced therapeutics growth of nearly 30%, and competitive wins in China, while CFO Adam Elinoff noted Biocare contributed $10 million in Q3 and about $23 million in Q4 guidance. Management also highlighted a reshoring opportunity sized at about $1 billion through 2030, with orders secured from five of the top ten pharma companies, and expects revenue from reshoring to begin in fiscal 2027.

The global bioinformatics market is projected to grow from $20.9 billion in 2024 to $43.5 billion by 2030, a compound annual growth rate of 13.1%, according to a new report by BCC Research. North America holds a 47.7% share, driven by institutional investment in genomic research and a mature biopharma ecosystem. Key drivers include AI and cloud computing integration, rising demand for personalized medicine and oncology applications, and emerging technologies such as long-read sequencing and single-cell multiomics. Major companies in the space include Illumina, Thermo Fisher Scientific, Agilent Technologies, and Dassault Systèmes.

Agilent Technologies has received European certification for its PD-L1 IHC 22C3 pharmDx test as a companion diagnostic for epithelial ovarian, fallopian tube, and primary peritoneal carcinoma, enabling pathologists to identify patients who may benefit from Merck's Keytruda. This marks the eighth CE-marked indication for the 22C3 assay in the EU, following an FDA approval of a related PD-L1 test for esophageal and gastric cancers nine days earlier. The approval extends the reach of an existing assay already used in labs worldwide, supporting Agilent's strategy of compounding its diagnostics footprint through incremental label expansions rather than relying on a single blockbuster product. The company also recently closed its acquisition of Biocare Medical to deepen its clinical pathology presence. However, Agilent faces competition from Danaher's Leica Biosystems, which is strengthening its own pathology pipeline with the planned acquisition of StatLab Medical Products, and the broader life sciences tools sector remains sensitive to growth outlook revisions, as seen when Danaher's stock fell 14% after trimming its core revenue growth forecast.

Agilent Technologies received U.S. Food and Drug Administration approval for its PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic to identify patients with several gastric and esophageal cancers who may be eligible for treatment with Bristol Myers Squibb's OPDIVO and OPDIVO QVANTIG, for use exclusively on the Agilent Autostainer Link 48 platform. The approval deepens Agilent's role in immuno-oncology testing by tying its assay directly to widely used PD-1 therapies in high-mortality gastrointestinal cancers. The new FDA approval strengthens Agilent's oncology diagnostics footprint, but on its own is unlikely to change the near-term earnings trajectory or overshadow existing risks around tariffs, supply chain complexity, and potential funding pressures in academic and government labs. Agilent's narrative projects $8.8 billion revenue and $2.1 billion earnings by 2029, with a fair value estimate of $161.00, representing a 16% upside to its current price.

Agilent Technologies has received European Union certification for its PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who may be eligible for treatment with Merck's KEYTRUDA. The approval is based on the KEYNOTE-B96/ENGOT-ov65 clinical trial and marks the eighth CE-marked indication for this assay in the EU. The test enables pathologists to assess PD-L1 expression in these tumor types, supporting treatment decisions in the platinum-resistant setting where options remain limited. Agilent developed the assay in partnership with Merck, and it is already indicated for several other cancers including non-small cell lung cancer and triple-negative breast cancer.

The global high-throughput screening market is projected to grow from USD 27.66 billion in 2026 to USD 45.90 billion by 2031, at a compound annual growth rate of 10.7 percent, according to a new report from MarketsandMarkets. Growth is driven by rising pharmaceutical and biotechnology R&D investments, increasing adoption of automated drug discovery platforms, and technological advances in areas such as cell-based screening and artificial intelligence-enabled analytics. The products segment accounted for the largest share of the market in 2025, with reagents, kits and consumables being the largest product type due to their recurring use across screening workflows. Asia Pacific is expected to register the highest growth rate during the forecast period, supported by expanding research activities and growing contract research organization presence in countries including China, India, Japan, and South Korea. Key players in the market include Thermo Fisher Scientific, Agilent Technologies, Merck KGaA, Danaher Corporation, and Revvity, with the top participants collectively holding approximately 38 percent of the global market.

Agilent Technologies has led a multimillion dollar investment round in HALO X-ray Technologies, with existing investors UK Innovation Science Seed Fund and the Midland Engine Investment Fund also participating. The funding will enable HALO to complete regulatory approval of its advanced X-ray diffraction security screening technology ahead of production and commercial scale-up. HALO's technology helps security operators distinguish genuine threats from everyday items more precisely than conventional X-ray systems, addressing pressure on airports and border agencies to improve throughput without compromising security. Agilent's Vice President and General Manager of the Spectroscopy & Vacuum Division, Geoff Winkett, said the further investment reflects confidence in the transformative potential of HALO's technology and team. HALO CEO Simon Godber called the round transformational, providing the runway needed to bring the technology to a global market.

The global mass spectrometry market is projected to grow from USD 6.68 billion in 2025 to USD 14.09 billion by 2035, at a compound annual growth rate of 7.74 percent, according to a new report by SNS Insider. The instruments segment held a dominant 71.34 percent market share in 2025, while the software and services category is the fastest-growing at a CAGR of 8.92 percent. North America leads the market, with the U.S. market alone valued at USD 2.38 billion in 2025 and expected to reach USD 4.97 billion by 2035, while Asia Pacific is the fastest-growing region at a CAGR of 9.12 percent. Key drivers include rising adoption in pharmaceutical manufacturing, omics research, and clinical diagnostics, with recent product launches such as Thermo Fisher Scientific's Orbitrap Astral mass spectrometer and Agilent Technologies' next-generation triple quadrupole LC-MS/MS system.

The global life science tools market is projected to grow from USD 175.96 billion in 2025 to USD 503.69 billion by 2035, at a compound annual growth rate of 11.09%, according to a new report by SNS Insider. North America led the market in 2025, with the U.S. segment valued at USD 68.50 billion and forecast to reach USD 189.48 billion by 2035, while the Asia-Pacific region is expected to record the fastest growth at a CAGR of more than 12%. Next-generation sequencing held the largest technology share at over 30% in 2025 and is also the fastest-growing technology segment, driven by applications in single-cell sequencing, liquid biopsy, and rare diseases. Instruments accounted for more than 52% of the market by type, and biopharmaceutical companies represented the largest end-user segment with an estimated 44% share. Key players include Agilent Technologies, Illumina, Thermo Fisher Scientific, and Danaher, with recent developments such as Agilent's expansion of its genomics portfolio in 2025 and Illumina's enhanced sequencing platforms in 2024.

Agilent Technologies has received FDA approval for its PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma, gastric, gastroesophageal junction, and esophageal adenocarcinoma who may be eligible for treatment with Bristol Myers Squibb's OPDIVO or OPDIVO QVANTIG. The test detects PD-L1 expression using a Combined Positive Score of at least one and is approved for exclusive use with the Agilent Autostainer Link 48. Clinical studies CheckMate-648 and CheckMate-649 showed improved overall survival and progression-free survival in patients treated with these immunotherapies. Esophageal cancer accounts for over 510,000 new cases and 445,000 deaths annually worldwide, while gastric cancer accounts for around 968,000 new cases and 660,000 deaths each year.

The global gas chromatography market is projected to grow from USD 3.65 billion in 2025 to USD 6.03 billion by 2035, at a compound annual growth rate of 5.15%, according to a new report by SNS Insider. North America held the largest share in 2025 at approximately 43.2%, with the U.S. market alone valued at USD 1.45 billion and expected to reach USD 2.34 billion by 2035. The pharmaceutical and biotechnology companies segment dominated end-use, driven by drug discovery and quality control applications, while the columns segment led accessories and consumables. Asia Pacific is expected to register the fastest growth, supported by expanding pharmaceutical manufacturing and laboratory infrastructure in China, India, and Japan. Recent developments include Shimadzu launching seven new gas chromatography systems in 2025 and Agilent Technologies introducing the 8850 Gas Chromatograph in 2024.

The South Korea automated liquid handling system market is projected to grow from $23.5 million in 2025 to $51.0 million by 2036, at a compound annual growth rate of 7.47%. The automated liquid handling system segment is expected to dominate by type, while liquid handling workstations lead by product. Drug discovery is the leading application, and pharmaceutical and biotechnology companies are the primary end users. Key players include Agilent Technologies, Revvity, Thermo Fisher Scientific, Danaher, and Tecan Group.

Agilent Technologies has launched xCELLigence RTCA eSight AI, a new AI-powered software module that automates label-free live-cell imaging analysis, as part of its broader push into AI-enabled laboratory solutions. The module integrates AI-driven image analysis with impedance measurements on the xCELLigence RTCA eSight platform, replacing manual cell segmentation with a one-click workflow to improve consistency and reduce analysis time. The company also announced a China Innovation Center in June 2026 focused on AI, automation, and digital laboratory technologies. For the third quarter of fiscal 2026, Agilent expects revenues between $1.83 billion and $1.85 billion, implying reported growth of 5.0% to 6.5%. The Zacks Consensus Estimate for third-quarter revenue is $1.84 billion, with earnings per share pegged at $1.47, indicating year-over-year growth of 7.30%.

Evercore ISI analyst Vijay Kumar raised the firm's price target on Agilent Technologies to $148 from $144 while maintaining an Outperform rating. The revision was part of the firm's second-quarter outlook for the MedTech, Life Sciences Tools, and Diagnostics sectors, noting that industry trends remain supported by generally stable procedure volumes and capital spending activity. Separately, Agilent introduced the xCELLigence RTCA eSight AI, an artificial intelligence-enabled software module that improves label-free imaging analysis by reducing manual cell segmentation and parameter adjustments. The new module integrates AI-based imaging analysis with the platform's existing dual-readout technology, allowing users to collect both imaging and impedance data from identical cells within a single experiment.

Agilent Technologies stock appears undervalued based on a Discounted Cash Flow analysis, which estimates an intrinsic value of about $174 per share, roughly 25.1% above the current market price. The company generated around $1.06 billion in free cash flow over the last twelve months, and the recent launch of the AI-powered xCELLigence RTCA eSight analysis module supports expectations for future cash generation. However, the stock trades at about 26.1 times earnings, which is above a tailored fair P/E ratio of roughly 23.6 times, suggesting overvaluation on an earnings basis. Broader valuation checks lean supportive, with the stock screening as undervalued in five of six metrics, leaving the key question as whether demand for life sciences tools and software can sustain both the cash flow assumptions and the current earnings multiple.

The global mobile mass spectrometers market is projected to grow from USD 1.68 billion in 2026 to USD 2.87 billion by 2031, at a compound annual growth rate of 11.3%. This growth is driven by increasing demand for real-time, on-site chemical analysis across sectors such as environmental monitoring, defense, and forensics. Ion sources held the largest component share in 2025 due to their critical role in sample ionization and the adoption of ambient ionization techniques. Field-deployable and backpack-based platforms led the product segment, valued for their portability and rapid deployment. North America is expected to maintain a dominant market position, supported by local manufacturing and strategic initiatives from key players including 1st Detect Corporation, 908 Devices, and Agilent Technologies.

Agilent Technologies reported second-quarter fiscal 2026 earnings of $1.49 per share, up 13.7% year over year and surpassing the Zacks Consensus Estimate by 6.21%. Quarterly revenues came in at $1.84 billion, representing 10% reported growth and beating estimates by 2.12%. The company raised its full-year revenue guidance to a range of $7.39 billion to $7.49 billion, with core revenue growth projected between 4.5% and 6.0%, and lifted its full-year non-GAAP earnings forecast to $6.00 to $6.10 per share. For the third quarter, Agilent expects revenues of $1.83 billion to $1.85 billion and non-GAAP earnings of $1.48 to $1.50 per share. Shares have added about 0.1% since the last earnings report, outperforming the S&P 500.

Agilent Technologies shares rose 4.5% to $137.61 after the company announced the completion of its acquisition of Biocare Medical, a clinical pathology firm focused on cancer diagnostics and research. The deal is expected to be accretive to Agilent's top-line growth rate and margin profile within the first year, and to begin contributing to earnings per share approximately 12 months after closing. The acquisition expands Agilent's pathology business and signals a clear path to increased profitability from the new business.

The 10 research tools and consumables stocks tracked by StockStory reported mixed first-quarter results, with aggregate revenues beating analyst consensus by 1.3% and next-quarter revenue guidance coming in 2% above expectations. Thermo Fisher posted revenues of $11.01 billion, up 6.2% year on year and exceeding estimates by 1.5%, though its stock fell 5.2% after the report. Waters Corporation delivered the strongest performance among peers, with revenues of $1.27 billion surging 91.5% year on year and beating estimates by 4.5%, driving a 22.3% stock gain. Revvity reported revenues of $686.9 million, up 9.3% but missing estimates by 2.6%, while Bio-Techne's revenues declined 1.5% to $311.4 million, lagging expectations by 1.6%. Agilent Technologies posted revenues of $1.84 billion, up 10% and topping estimates by 1.9%, with its stock rising 13.6%.

Piper Sandler initiated coverage of Agilent Technologies with a Neutral rating and a $150 price target. The firm launched coverage of the life science tools sector, preferring to wait for clearer signs of future growth drivers before turning more positive on additional companies in the space. Piper Sandler noted that challenges related to biotech and academic spending, along with China-related exposure, could improve in the near term. Separately, Agilent announced a strategic collaboration with OpenAI and Boston Consulting Group to expand the use of artificial intelligence across its business operations, product development, and customer solutions.

Excellere Partners and GHO Capital have completed the sale of Biocare Medical to Agilent Technologies. Under their ownership, Biocare achieved annual double-digit revenue and profitability growth, strengthened its core immunohistochemistry business, expanded into molecular diagnostics through acquisition, and reinforced its executive leadership team. The acquisition combines two businesses with closely aligned strategies in life sciences and diagnostics, expected to unlock greater market access, enhanced customer support, and accelerated innovation for Biocare's customers worldwide.

The global drug discovery technologies market is projected to grow from USD 30.58 billion in 2025 to USD 51.51 billion in 2030, at a compound annual growth rate of 11 percent. The in-silico and AI-based drug discovery segment is experiencing the highest CAGR within the forecast period, driven by its ability to shorten timelines, reduce costs, and enhance drug success rates through computational modeling, machine learning, and data analytics. Oncology claims the largest share of the market, fueled by rising cancer incidence and the push for personalized therapies. The United States is anticipated to show the highest growth rate, supported by a robust pharmaceutical and biotech presence, advanced research infrastructure, and active oncology programs. Key industry players include Thermo Fisher Scientific Inc., Danaher Corporation, Agilent Technologies, Inc., and Illumina, Inc.

Agilent Technologies reported quarterly results that exceeded analyst expectations on both revenue and earnings, and the company raised its full-year guidance. The stock is trading at $127.06, while the most followed analyst narrative points to a fair value of $161, implying a potential undervaluation of about 23%. Strategic investments in higher-margin recurring revenue streams such as consumables, software, services, and digital platforms are gaining traction, with CrossLab and services delivering consistent mid-single-digit growth. However, pressure points remain, including elevated tariff-related costs and potential further weakening in academic and government funding.

Agilent Technologies announced plans to open a new China Innovation Center focused on digital, AI, and automation research and development, alongside the acquisition of Biocare to expand its presence in cancer diagnostics. The company's stock trades at $127.06, up 10.7% over the past 30 days and 10.9% over the past year, though it is down 7.9% year to date and 10.7% over five years. Analysts have a consensus target of about $160.35, roughly 21% above the current price, while a Simply Wall St valuation estimates the stock is trading about 23.2% below fair value. The initiatives push Agilent further into AI, automation, and cancer diagnostics, with attention likely to focus on execution milestones such as Biocare integration and R&D progress at the new center.

Agilent Technologies reported first-quarter revenues of $1.84 billion, a 10% year-on-year increase that exceeded analyst expectations by 1.9%. The company, which was spun off from Hewlett-Packard in 1999, also delivered an impressive beat on organic revenue estimates and a narrow beat on full-year EPS guidance. Among the ten research tools and consumables stocks tracked, Agilent scored the highest full-year guidance raise but had the weakest guidance update of the group. Its stock has risen 7.6% since the report, trading at $124.70. The broader subsector saw revenues beat consensus by 1.3% on average, with next-quarter guidance coming in 2% above expectations, and share prices have been resilient, up 8.5% on average since earnings.

The global automated liquid handling systems market is projected to grow from an estimated USD 2.9 billion in 2026 to around USD 6.9 billion by 2035, at a compound annual growth rate of 9.8 percent, according to a new report by Healthcare Foresights. The market was valued at approximately USD 2.7 billion in 2025. Growth is driven by expanding pharmaceutical and biotech research and development, rising demand for high-throughput screening, and technological advances in robotics and artificial intelligence. North America currently dominates the market, while the Asia Pacific region is expected to register the highest growth rate. Key players include Eppendorf SE, Perkin Elmer Inc., Danaher Corp., Agilent Technologies Inc., Thermo Fisher Scientific Inc., and QIAGEN NV.

The global fluorescent in situ hybridization probe market is forecast to grow from an estimated USD 1.14 billion in 2025 to around USD 2.27 billion by 2035, at a compound annual growth rate of 7.9 percent, according to a new report by Healthcare Foresights. The market is expected to reach USD 1.23 billion in 2026. Growth is driven by rising cancer and genetic disorder prevalence, increasing adoption of personalized medicine, and technological advances such as multiplexed probes and AI-enhanced analysis. DNA probes held the largest product segment in 2025, while North America leads the market and Asia Pacific is the fastest-growing region. Key players include Thermo Fisher Scientific, Abbott Laboratories, and Agilent Technologies.